

# EUFEMED

European  
Federation for  
Exploratory  
Medicine  
Development

Born 20-May-2015  
Brussels



Dr Mike Hammond  
Dr Jörg Täubel

# EUFEMED – Associations sharing common goals

- Promotion of Best Practice
- Providing Opportunities for Interaction and Information Exchange
- Education and training with an International Perspective
- Promotion of European Early Phase Clinical Development
- Recognition as a Credible Stakeholder in the Future Direction of Clinical Development
- Interface with National and International Regulatory Agencies (EMA)

# Founder Members



**CLUB PHASE 1**

# Was it an easy birth?

- Required a formal legal arrangement including harmonisation between the national societies
- Many redrafts of legal documents and financial and tax document
- Choosing the LOGO – final agreement the night before the inaugural conference!
- Good natured and cooperative

Brussels 2015

EU Federation for Exploratory Medicines Development  
the present: getting married

▪ Married on 12 May 2015






EU Federation for Exploratory Medicines Development  
the present: getting married

▪ Married on 12 May 2015





Home
Important info
Committees
Host city and venue
Pre-conference workshops
Scientific programme 21 & 22 May
DOWNLOAD PRESENTATIONS
Speakers
Registration
Accommodation
Social programme
Organisers
Sponsors
Previous editions
Contact



## Welcome

After successful meetings in Berlin (2011) and Nice (2013), the four European early clinical drug development organizations from Belgium (BAPU), France (Club Phase 1), Germany (AGAH) and the United Kingdom (AHPPI), have the pleasure of inviting you to their 3rd joint conference in 2015.

The 2015 conference takes place on **21-22 May in Brussels** and is hosted by the Belgian Association of Phase I Units (BAPU). As BAPU was founded in January 2005, on this occasion also the 10th anniversary of BAPU will be celebrated.

The conference takes place in the centrally located and inspiring Square Brussels meeting center. It is organized by and for professionals in early clinical drug development. The focus of the meeting is on the **competitiveness of Europe in early clinical drug development**, the impact of the new European regulation as well as the challenges encountered in conducting exploratory clinical studies in a continuously changing environment. Next to five sessions of presentations given by experts in the field, several parallel workshops provide ample time for lively discussions and to go into detail on different aspects of early clinical research.

**Two parallel 1-day pre-conference workshops are organized on 20 May.** On that day you can either get fully informed about the new EU regulation or attend a full day workshop dedicated to pharmacokinetic and pharmacodynamic modeling.

In order to create a "European voice" for exploratory medicines development, AGAH, AHPPI, BAPU and Club Phase 1 decided to join forces for more structured future collaborations by setting up a **European Federation for Exploratory Medicines Development – EUFEMED**. Our 3rd joint conference is the ideal occasion for the inauguration of EUFEMED and for celebrating its foundation.

We look forward to meeting you in Brussels: the place to be for professionals!

*On behalf of the organising associations,*

Prof. Dr. Jan de Hoon  
BAPU

Dr. Y. Donazzolo  
Club Phase I

Prof. Dr. H. Sourgens  
AGAH

Dr. P. Dewland  
AHPPI

With the financial support of [visit.brussels](http://visit.brussels)

# Berlin 2011

# Nice 2013


# Brussels 2015



CLUB PHASE 1



Home
Important info
Committees
Host city and venue
Pre-conference workshops
Scientific programme 21 & 22 May
DOWNLOAD PRESENTATIONS
Speakers
Registration
Accommodation
Social programme
Organisers
Sponsors
Previous editions
Contact



## Welcome

After successful meetings in Berlin (2011) and Nice (2013), the four European early clinical drug development organizations from Belgium (BAPU), France (Club Phase 1), Germany (AGAH) and the United Kingdom (AHPPI), have the pleasure of inviting you to their 3rd joint conference in 2015.

The 2015 conference takes place on **21-22 May in Brussels** and is hosted by the Belgian Association of Phase I Units (BAPU). As BAPU was founded in January 2005, on this occasion also the 10th anniversary of BAPU will be celebrated.

The conference takes place in the centrally located and inspiring Square Brussels meeting center. It is organized by and for professionals in early clinical drug development. The focus of the meeting is on the **competitiveness of Europe in early clinical drug development**, the impact of the new European regulation as well as the challenges encountered in conducting exploratory clinical studies in a continuously changing environment. Next to five sessions of presentations given by experts in the field, several parallel workshops provide ample time for lively discussions and to go into detail on different aspects of early clinical research.

**Two parallel 1-day pre-conference workshops are organized on 20 May.** On that day you can either get fully informed about the new EU regulation or attend a full day workshop dedicated to pharmacokinetic and pharmacodynamic modeling.

In order to create a "European voice" for exploratory medicines development, AGAH, AHPPI, BAPU and Club Phase 1 decided to join forces for more structured future collaborations by setting up a **European Federation for Exploratory Medicines Development – EUFEMED**. Our 3rd joint conference is the ideal occasion for the inauguration of EUFEMED and for celebrating its foundation.

We look forward to meeting you in Brussels: the place to be for professionals!

*On behalf of the organising associations,*

Prof. Dr. Jan de Hoon  
BAPU

Dr. Y. Donazzolo  
Club Phase I

Prof. Dr. H. Sourgens  
AGAH

Dr. P. Dewland  
AHPPI

With the financial support of [visit.brussels](http://visit.brussels)

# Berlin 2011

# Nice 2013

# Brussels 2015

# London 2017



CLUB PHASE 1





# Q20: Would you attend EUFEMED Conference (Joint Conference of the European Human Pharmacological Societies) in the future?

Answer Choices	Responses	
Yes	84.44%	38
No	0.00%	0
Not sure	15.56%	7
Total		45

Q15: Please answer the questions below. Rate on a scale from 5 (very positive), over 3 (average) to 1 (rather negative)

	5	4	3	2	1	Total
Did the event meet your expectations?	<b>33.33%</b> 16	<b>54.17%</b> 26	<b>12.50%</b> 6	<b>0.00%</b> 0	<b>0.00%</b> 0	48
Were the topics relevant to you/your job?	<b>16.67%</b> 8	<b>60.42%</b> 29	<b>20.83%</b> 10	<b>2.08%</b> 1	<b>0.00%</b> 0	48
Did you get answers to your doubts/questions?	<b>10.42%</b> 5	<b>54.17%</b> 26	<b>31.25%</b> 15	<b>4.17%</b> 2	<b>0.00%</b> 0	48
Have you received some new information?	<b>35.42%</b> 17	<b>50.00%</b> 24	<b>12.50%</b> 6	<b>2.08%</b> 1	<b>0.00%</b> 0	48

# Aims?

- Meetings – national and international
- Developing training programme with international flavour
- Cooperation with other societies within EUFEMED and outside e.g. British Pharmacological Society, Institute of Clinical Research, American College of Clinical Pharmacology ..... ACCP AM 2016
- Recognition as Stakeholders by Regulatory Authorities both national and Regional



# How can YOU participate?

- EUFEMED has no Individuals as Members
- Join your National Early Phase Development / Clinical Research Society
- Commercial Organisations can become Associate Members
- If not already a member of EUFEMED lobby your society to apply
- Be prepared to contribute your time and enthusiasm to the success of your national organisation and EUFEMED



# Diploma Course

- It is planned that the course will lead to a certificate or diploma (30 ECTS)
  - in accordance with Pharmatrain requirements -
  - and for medical doctors also to a PI qualification.
- Organised by EUFEMED
- There are four country associations involved: UK, Germany, Belgium and France.



# Diploma Course

Modules 1-7	Organiser
Introductory Module (5 days) – established in 2014	AGAH
PK PD PK/PD biomarkers (6 days)	BAPU
Non clinical safety / Safety / Pharmacovigilance (5-6 days)	CPI
Principal Investigator* / Study Director / Study management / Data management / Biometrics (5-6 days)	<b>AHPPI</b>
Biologics / Advanced Therapies (5 days)	AGAH
Study design / Special populations / FIM / Oncology (5-6 days)	CPI (lead) / BAPU
Pharmaceutics / Trial medication / Regulatory issues / GxP / Quality assurance (5 days)	<b>AHPPI</b>





# Diploma Course

- The organisers are responsible for the syllabus, organisation and selecting speakers
- Speakers will be invited from across Europe
- University accredited
- Blended learning: f2f, web-based, self-study, exercises, assignments ...
- Stand-alone modules can be booked
- Course language is English

# Questions?

